Partial safety of the new COX-2 inhibitor rofecoxib in NSAIDs high sensitive patients

Allergy. 2004 Oct;59(10):1133-4. doi: 10.1111/j.1398-9995.2004.00532.x.

Authors

A Matucci¹, P Parronchi, A Vultaggio, O Rossi, F Brugnolo, E Maggi, S Romagnani

Affiliation

¹ Department of Internal Medicine, Section of Immunoallergology and Respiratory Diseases, University of Florence, Policlinico di Careggi Viale Morgagni 85, 50134 Florence, Italy. a.matucci@dmi.unifi.it

PMID: 15355480
DOI: 10.1111/j.1398-9995.2004.00532.x

No abstract available

MeSH terms

Adolescent
Adult
Aged
Anti-Inflammatory Agents, Non-Steroidal / immunology*
Cross Reactions
Cyclooxygenase Inhibitors / immunology*
Drug Hypersensitivity / immunology*
Female
Humans
Lactones / immunology*
Male
Middle Aged
Sulfones / immunology*
Treatment Outcome

Substances

Anti-Inflammatory Agents, Non-Steroidal
Cyclooxygenase Inhibitors
Lactones
Sulfones
rofecoxib